A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/22/2019
Start Date:April 2014
End Date:October 2020
Contact:Steve Demas
Email:sdemas@helixbiopharma.com
Phone:905-841-2300

Use our guide to learn which trials are right for you!

A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination With Pemetrexed/Carboplatin in Patients With Stage IV (TNM M1a and M1b) Recurrent or Metastatic NSCL Lung Cancer

The primary purpose of this research study is to evaluate how safe, how well tolerated and
how effective a range of doses of L-DOS47 in combination with standard doublet therapy of
pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic
non-squamous Non-Small Cell Lung Cancer.

It is planned that patients will receive 4 cycles of combination treatment with L-DOS47 +
pemetrexed/carboplatin. Patients who have not progressed following the 4 cycles of
combination treatment and who have not experienced unacceptable toxicity will have the
opportunity to continue to receive L-DOS47 treatment for as long as there is clinical benefit
and it is well-tolerated, in the opinion of the Investigator, until disease progression.
Patients who are unable to complete 4 cycles of L-DOS47 + pemetrexed/carboplatin combination
treatment due to pemetrexed/carboplatin toxicity will have the opportunity to continue
receiving L-DOS47 treatment following discontinuation of pemetrexed/carboplatin, for as long
as there is clinical benefit and it is well-tolerated, in the opinion of the Investigator,
until disease progression.

Main Inclusion Criteria:

1. Male or female patient ≥ 18 years of age

2. Histologically or cytologically confirmed non-squamous NSCLC

3. EGFR-mutation positive patients must have progressed on or had intolerance to an EGFR
small molecule tyrosine kinase inhibitor

4. Patients whose tumors harbor an anaplastic lymphoma kinase (ALK) translocation must
have progressed on or had intolerance to an ALK inhibitor;

5. No prior adjuvant chemotherapy within 1 year of the first treatment day if there is
recurrent disease

6. At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors
(RECIST) v1.1

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and minimum
life expectancy of ≥ 3 months

8. Adequate bone marrow, renal and liver function

Main Exclusion Criteria:

1. Histologic evidence of predominantly squamous cell NSCLC

2. Brain metastasis and/or leptomeningeal disease (known or suspected)

3. Peripheral neuropathy > CTCAE grade 1

4. Possibility of a curative local treatment (surgery and/or radiotherapy)

5. Previous chemotherapy except adjuvant treatment with progression of disease documented
≥ 12 months after end of adjuvant treatment

6. Having received treatment in another clinical study within the 30 days prior to
commencing study treatment or having side effects of a prior study drug that are not
recovered to grade ≤ 1 or baseline, except for alopecia

7. Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy
We found this trial at
2
sites
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials